Study type: In vivo/preclinical · Status: Citation identity verified
Fusion of thymosin alpha 1 with mutant IgG1 CH3 prolongs half-life and enhances antitumor effects in vivo.
International immunopharmacology · 2019
Study scale: Not reported
Citation only: Open source record
Product or molecular entity relationships
- Thymosin Alpha 1: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Not reported in the reviewed source.
Methods
Not reported in the reviewed source.
Scale or participants
Not reported in the reviewed source.
Key findings
Not reported in the reviewed source.
Limitations and uncertainty
Not reported in the reviewed source.
Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.